BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2025 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.200-4.400 for the period, compared to the consensus EPS estimate of 4.160. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BMRN. Evercore ISI dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Citigroup lowered their target price on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Royal Bank of Canada restated a “sector perform” rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday. Robert W. Baird lowered their target price on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group lowered their target price on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.65.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock traded up $3.09 during midday trading on Thursday, hitting $68.70. The stock had a trading volume of 1,711,017 shares, compared to its average volume of 1,512,691. The firm’s fifty day moving average is $64.79 and its two-hundred day moving average is $71.06. The company has a market capitalization of $13.09 billion, a PE ratio of 41.18, a P/E/G ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical has a 52-week low of $60.63 and a 52-week high of $94.85. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. On average, research analysts forecast that BioMarin Pharmaceutical will post 2.5 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.